In vivo efficacy study of BMS-986365 and enzalutamide in mCRPC PDX models

This study is aimed to explore in vivo trascriptional response of BMS-986365 and enzalutamide in mCRPC PDX models CTG-2441 and CTG-2440 which were derived from bone metastases of the same patient following progression on ADT or ADT plus abiraterone treatments, respectively. Male NOG immunocompromised mice were implanted subcutaneously into the left flank with tumor fragments from CTG-2441 and CTG02440 prostate cancer models. Mice were dose with 7 days of QD dosing by oral gavage of vehicle, BMS-986365 (60 mg/kg), and ENZ (50 mg/kg) and carried out at Champions Oncology (Rockville, MD, USA). At 6 hours post final dose, tumor samples were collected and RNA-seq was performed.